Didric Cederholm Portfolio
Invests via Lion Point Capital LP | Managed by Didric Cederholm, Jim Freeman
Invests via Lion Point Capital LP
Managed by Didric Cederholm, Jim Freeman
Automatically Tracked
Active in Nordic venture circles, Didric Cederholm is an angel investor and operator who blends hands-on product and growth experience with early-stage capital deployment. He invests primarily into SaaS, fintech and developer tooling companies across Northern Europe, writing direct checks and leading small syndicates while providing go-to-market support. His background includes founding and scaling startups, early-team product leadership, and board-advisory roles that help translate technical roadmaps into commercial traction. Capital partners and founders cite his operational involvement as a catalyst for Series A readiness, and he sources deals through operator networks and founder referrals. Investment scope centers on pre-seed to Series A rounds with an emphasis on founder-led technical teams and measurable ARR or user-growth signals.
Active in Nordic venture circles, Didric Cederholm is an angel investor and operator who blends hands-on product and growth experience with early-stage capital deployment. He invests primarily into SaaS, fintech and developer tooling companies across Northern Europe, writing direct checks and leading small syndicates while providing go-to-market support. His background includes founding and scaling startups, early-team product leadership, and board-advisory roles that help translate technical roadmaps into commercial traction. Capital partners and founders cite his operational involvement as a catalyst for Series A readiness, and he sources deals through operator networks and founder referrals. Investment scope centers on pre-seed to Series A rounds with an emphasis on founder-led technical teams and measurable ARR or user-growth signals.
Investment Philosophy & Strategy
Operator-led angel strategy focused on pre-seed to Series A SaaS, fintech and developer tooling in Northern Europe. Prioritises founder-led technical teams with measurable ARR or user-growth signals, deploying concentrated checks and leading small syndicates. Emphasises capital efficiency and milestone-driven follow-ons, pairing go-to-market and product growth support to accelerate Series A readiness. Underwrites opportunities through operator networks and referrals, prefers pragmatic risk management via hands-on board/advisory involvement and clear commercial traction metrics.
Operator-led angel strategy focused on pre-seed to Series A SaaS, fintech and developer tooling in Northern Europe. Prioritises founder-led technical teams with measurable ARR or user-growth signals, deploying concentrated checks and leading small syndicates. Emphasises capital efficiency and milestone-driven follow-ons, pairing go-to-market and product growth support to accelerate Series A readiness. Underwrites opportunities through operator networks and referrals, prefers pragmatic risk management via hands-on board/advisory involvement and clear commercial traction metrics.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
35.87%
Gain +3.64%
Monthly
0.85%
Yearly
10.75%
Drawdown
42.58%
$20.9M
Equity
Holdings
$20.9M
Investment
$19.33M
$307.82M
Profit +$730,829.26
Realized
$306.25M
Unrealized
$1.57M
Dividends
$21.07M
Goals
Avg. 77.67% completed goals
Yearly
Gain > 9% 2026
Yearly
Loss < 33% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
3.64%
Profit
$730,829.26
Win %
57%
This Week
Compared To Last Week
Gain
4.46%
Profit
$892,736.14
Win %
57%
This Month
Compared to last month
Gain
5.47%
Profit
$1.08M
Win %
57%
This Year
Compared to last year
Gain
3%
Profit
$605,469.08
Win %
59%
CUE Cue Biopharma, Inc.
+10.04%
+$165,135.36 
HUMA Humacyte, Inc.
+10%
+$35,750.01 
KURA Kura Oncology Inc.
+7.63%
+$35,420 
SPRB Spruce Biosciences Inc.
+5.77%
+$2,870 
GHRS GH Research plc
+4.61%
+$13,260 
SNDX Syndax Pharmaceuticals Inc.
+3.98%
+$27,360 
RCKT Rocket Pharmaceuticals Inc.
+3.89%
+$11,180 
ARDX Ardelyx Inc.
+3.71%
+$18,654.25 
QURE uniQure N.V.
+3.3%
+$22,858.49 
MIST Milestone Pharmaceuticals Inc.
+2.8%
+$24,600 
EWTX Edgewise Therapeutics, Inc.
+2.29%
+$9,009 
INVA Innoviva Inc.
+2.12%
+$3,608 
ARQT Arcutis Biotherapeutics Inc.
+1.39%
+$1,890 
MCRB Seres Therapeutics, Inc.
+1.34%
+$1,894.2 
VTRS Viatris Inc.
+1.28%
+$5,678.47 
CMPS Compass Pathways plc Depositary Receipt
+1.2%
+$12,800 
RGNX Regenxbio Inc.
+0.98%
+$2,793 
JANX Janux Therapeutics Inc.
+0.75%
+$2,280 
RPRX Royalty Pharma plc
+0.07%
+$856 
LNTH Lantheus Holdings, Inc.
+0.01%
+$55 
BNTC Benitec Biopharma Inc.
0%
$0 
IPHA Innate Pharma S.A. Sponsored ADR
-14%
-$28,808.6 
JSPR Jasper Therapeutics Inc.
-8.46%
-$33,944.98 
GERN Geron Corporation
-4.54%
-$40,460 
FENC Fennec Pharmaceuticals Inc.
-2.82%
-$38,227.56 
MLYS Mineralys Therapeutics, Inc.
-1.73%
-$4,725 
SRPT Sarepta Therapeutics Inc.
-1.71%
-$8,977.5 
BBIO BridgeBio Pharma, Inc.
-1.66%
-$6,750 
AZTA Azenta, Inc.
-1.56%
-$5,141 
IRON Disc Medicine Inc.
-1.46%
-$9,477.02 
BHVN Biohaven Ltd.
-1.41%
-$10,857 
DYN Dyne Therapeutics Inc.
-1%
-$4,680 
PCRX Pacira BioSciences Inc.
-0.78%
-$2,430 
PRAX Praxis Precision Medicines Inc.
-0.45%
-$7,342.46 
MLTX MoonLake Immunotherapeutics
-0.18%
-$2,025 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 497 | Longs Won 271/497 54% | Profit Factor 1.78 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $5.97M |
| Average Win $2.59M | Best Trade (Dec 31) $64.29M | Sharpe Ratio -12.35 |
| Average Loss -$1.74M | Worst Trade (Sep 29) -$37.03M | Z-Score -2.26 (100%) |
| Commissions $0 | Avg. Trade Length 1y 3m 1w | Expectancy $619,359.4 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | 24.16% | 37.05% | 47.58% | 56.82% | 65.2% | 72.97% | 80.25% | 87.14% | 93.71% |
| Consecutive Losing Trades | 12 | 11 | 10 | 8 | 7 | 6 | 5 | 4 | 2 | 1 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx Inc. | 128,650 | $366,652.5 | $521,675.75 | - | $155,023.25 | 42.28% | +3.708% |
| ARQT Arcutis Biotherapeutics Inc. | 5,250 | $73,132.5 | $137,497.5 | - | $64,365 | 88.01% | +1.394% |
| AZTA Azenta, Inc. | 9,700 | $322,622 | $323,786 | - | $1,164 | 0.36% | -1.563% |
| BBIO BridgeBio Pharma, Inc. | 5,000 | $126,650 | $399,300 | - | $272,650 | 215.28% | -1.662% |
| BHVN Biohaven Ltd. | 51,700 | $1.46M | $756,888 | - | -$704,841 | -48.22% | -1.414% |
| BNTC Benitec Biopharma Inc. | 62,000 | $648,900 | $778,720 | - | $129,820 | 20.01% | 0.0 |
| CMPS Compass Pathways plc Depositary Receipt | 80,000 | $454,000 | $1.08M | - | $622,000 | 137% | +1.204% |
| CUE Cue Biopharma, Inc. | 52,928 | $1.35M | $1.81M | - | $458,356.48 | 33.91% | +10.039% |
| DYN Dyne Therapeutics Inc. | 18,000 | $352,080 | $462,600 | - | $110,520 | 31.39% | -1.002% |
| EWTX Edgewise Therapeutics, Inc. | 9,100 | $225,817 | $401,947 | - | $176,130 | 78% | +2.293% |
| FENC Fennec Pharmaceuticals Inc. | 112,434 | $957,842.22 | $1.32M | - | $359,884.26 | 37.57% | -2.819% |
| GERN Geron Corporation | 578,000 | $1.78M | $849,660 | - | -$931,500 | -52.3% | -4.545% |
| GHRS GH Research plc | 10,200 | $129,540 | $300,798 | - | $171,258 | 132.2% | +4.612% |
| HUMA Humacyte, Inc. | 650,000 | $633,421.25 | $393,250.01 | - | -$240,171.24 | -37.92% | +10% |
| INVA Innoviva Inc. | 8,200 | $163,918 | $173,758 | - | $9,840 | 6% | +2.12% |
| IPHA Innate Pharma S.A. Sponsored ADR | 81,151 | $142,014 | $176,909.18 | - | $34,895.18 | 24.57% | -14.004% |
| IRON Disc Medicine Inc. | 8,100 | $439,388 | $638,604 | - | $199,216 | 45.34% | -1.462% |
| JANX Janux Therapeutics Inc. | 19,000 | $262,200 | $306,280 | - | $44,080 | 16.81% | +0.75% |
| JSPR Jasper Therapeutics Inc. | 465,000 | $2.15M | $367,350.01 | - | -$1.79M | -82.94% | -8.459% |
| KURA Kura Oncology Inc. | 46,000 | $407,100 | $499,560 | - | $92,460 | 22.71% | +7.631% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Didric Cederholm?
The largest contributions to the portfolio's profits come from the following stocks: Canadian Solar Inc - $137.19M, Lattice Semiconductor Corporation - $123.67M, Marvell Technology, Inc - $37.33M, ORIG - $34.21M, and Ally Financial Inc - $31.74M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Comscore Inc - $44.75M, BurgerFi International Inc - $37.03M, PDC Energy Inc - $35.42M, CPE - $35.12M, and Carrizo Oil & Gas Inc - $29.94M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Didric Cederholm's portfolio generate?
The portfolio generates substantial dividend income, with a total of $21.07M earned over time. The largest contributors to dividend income include Chord Energy Corp - $6.63M, Ally Financial Inc - $2.94M, CenterPoint Energy Inc - $1.99M, Expand Energy Corporation - $1.79M, and Marvell Technology, Inc - $1.23M. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Didric Cederholm's monthly returns?
Didric Cederholm's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Didric Cederholm's strategy be considered aggressive or moderate?
Didric Cederholm's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Didric Cederholm's strategy?
Didric Cederholm's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
